Spyre Therapeutics, Inc.

WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 58,843 shares of common stock of Spyre and 2,134 restricted stock units (“RSUs”) to six non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on July 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

globenewswire.com - 2026-07-02 16:05:00

Spyre Therapeutics is building a long-acting antibody platform across IBD and rheumatology. However, they only have Phase 2 assets, with SPY001 and SPY002 that recently showed encouraging Part A data. We still need to wait to see their placebo-controlled data, as well as their combo therapy data.

seekingalpha.com - 2026-06-30 08:00:00

Spyre Therapeutics  SYRE has given investors a classic biotech dilemma. The pipeline is advancing, the cash balance is large and the stock has already moved sharply higher.

zacks.com - 2026-06-29 12:25:26

Spyre Therapeutics  SYRE has become a closely watched clinical-stage biotech stock as investors look ahead to a busy stretch of data readouts that could define the company's next phase. The company is focused on inflammatory bowel disease, or IBD, where it is developing long-acting antibodies and antibody combinations aimed at improving disease control, convenience and durability of response.

zacks.com - 2026-06-29 12:21:15

SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.

zacks.com - 2026-06-29 12:21:13

Spyre is building a modular immunology platform targeting IBD and rheumatic diseases with internally developed, long-acting antibody combinations. Positive Phase 2 data for SPY001 and SPY002 in ulcerative colitis validate SYRE's approach, with a third monotherapy readout and multiple rheumatology catalysts expected in 2026. SYRE's $1.18B cash position funds operations into 2H 2029, supporting robust clinical execution and mitigating near-term dilution risk.

seekingalpha.com - 2026-06-26 14:34:39

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.

etftrends.com - 2026-06-25 11:31:47

Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significantly ​reducing disease severity in a mid-stage trial.

reuters.com - 2026-06-15 08:28:57

SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p

globenewswire.com - 2026-06-15 08:00:00

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

etftrends.com - 2026-06-11 07:14:42

Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-08 12:58:33

WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 51,300 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on June 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

globenewswire.com - 2026-06-05 16:01:00

Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.

zacks.com - 2026-06-04 12:01:20

Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete

globenewswire.com - 2026-06-03 08:00:00

WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:

globenewswire.com - 2026-05-26 16:10:00

WALTHAM, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare Conference - New YorkDate: Wednesday, June 3, 2026Fireside Time: 12:15 pm ET Event: Goldman Sachs 47th Annual Global Healthcare Conference - MiamiDate: Monday, June 8, 2026Fireside Time: 10:00 am ET Members of the Spyre management team will also host one-on-one investor meetings during the conferences.

globenewswire.com - 2026-05-26 16:10:00

Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class  Announced over-enrollment and acceleration of topline readout to the third quarter of 2026 of the rheumatoid arthritis (“RA”) sub-study of the Phase 2 SKYWAY basket trial Remain on track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Further strengthened the balance sheet with $463 million gross proceeds from an underwritten public offering of common stock $1.2 billion in pro forma cash, cash equivalents, and marketable securities as of March 31, 2026 , with expected runway into the second half of 2029 WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases (“RD”), today announced its first quarter 2026 financial results and provided program and corporate updates.

globenewswire.com - 2026-05-05 08:00:00

WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 20,800 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on May 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

globenewswire.com - 2026-05-01 16:28:00

Spyre Therapeutics' stock rises 73% in a month after mid-stage data show strong efficacy and safety for SPY001 in ulcerative colitis, boosting investor optimism.

zacks.com - 2026-04-23 13:36:24

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 975,000 additional shares, at a public offering price per share of $62.00.

globenewswire.com - 2026-04-16 16:15:00